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Abstract
Few data exist regarding predictors of rapid aortic root dilation and referral for aortic surgery in Marfan syndrome (MFS). 
To identify independent predictors of the rate of aortic root (AoR) dilation and referral for aortic surgery, we investigated 
the data from the Pediatric Heart Network randomized trial of atenolol versus losartan in young patients with MFS. Data 
were analyzed from the echocardiograms at 0, 12, 24, and 36 months read in the core laboratory of 608 trial subjects, aged 
6 months to 25 years, who met original Ghent criteria and had an AoR z-score (AoRz) > 3. Repeated measures linear and 
logistic regressions were used to determine multivariable predictors of AoR dilation. Receiver operator characteristic curves 
were used to determine cut-points in AoR dilation predicting referral for aortic surgery. Multivariable analysis showed rapid 
AoR dilation as defined by change in AoRz/year > 90th percentile was associated with older age, higher sinotubular junction 
z-score, and atenolol use (R2 = 0.01) or by change in AoR diameter (AoRd)/year > 90th percentile with higher sinotubular 
junction z-score and non-white race (R2 = 0.02). Referral for aortic root surgery was associated with higher AoRd, higher 
ascending aorta z-score, and higher sinotubular junction diameter:ascending aorta diameter ratio (R2 = 0.17). Change in AoRz 
of 0.72 SD units/year had 42% sensitivity and 92% specificity and change in AoRd of 0.34 cm/year had 38% sensitivity and 
95% specificity for predicting referral for aortic surgery. In this cohort of young patients with MFS, no new robust predic-
tors of rapid AoR dilation or referral for aortic root surgery were identified. Further investigation may determine whether 
generalized proximal aortic dilation and effacement of the sinotubular junction will allow for better risk stratification. Rate 
of AoR dilation cut-points had high specificity, but low sensitivity for predicting referral for aortic surgery, limiting their 
clinical use. Clinical Trial Number ClinicalTrials.gov number, NCT00429364.
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Introduction
Marfan syndrome (MFS) is an autosomal dominant con-
nective tissue disorder affecting approximately 1 in 5000 
people [1]. Progressive aortic root (AoR) dilation leading 
to aortic dissection and rupture has long been recognized 
as the leading cause of death in MFS [2, 3]. Although the 
majority (60–80%) of patients with MFS have some degree 
of AoR dilation [4], there is lack of large multicenter studies 
evaluating the factors that predict the rate of aortic dilation 
and the need for aortic surgery among individual patients.
In healthy children and adults, AoR diameter correlates 
with age, height, weight, and body surface area [5–8]. In 
children and adults with MFS, larger baseline AoR diameter 
has been shown to predict progressive AoR dilation [9, 10]. 
Older age, increased height, higher systolic blood pressure, 
larger baseline AoR diameter, more rapid AoR dilation, 
and a pattern of generalized proximal aortic dilation have 
been shown to predict aortic complications such as aortic 
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regurgitation, aortic dissection and rupture, and death [4, 
11–15]. Previous studies have been limited by retrospective 
design, single-center enrollment, small sample size, and/or 
short follow-up times. Identification of more robust risk fac-
tors associated with rapid AoR dilation and need for aortic 
surgery would allow for better risk stratification to determine 
those who would most benefit from more frequent follow-
up and initiation of earlier medical therapy and/or surgical 
intervention.
The Pediatric Heart Network (PHN) Marfan trial enrolled 
608 subjects to compare the effects of beta blocker therapy 
(atenolol) versus angiotensin II receptor blocker therapy 
(losartan) on aortic dilation in individuals with MFS [16]. 
This trial provides one of the largest and most robust inter-
national databases for children and young adults with MFS 
who have significant aortic root involvement [17]. The pri-
mary aim of this study was to analyze data arising from the 
trial to identify independent clinical and echocardiographic 
predictors of the rate of AoR dilation, including annual rate 
of change in AoR z-score (AoRz)/year and in AoR diameter 
(AoRd)/year. The secondary aims were to determine inde-
pendent clinical and echocardiographic predictors of rapid 
AoR dilation (change in AoRz/year and AoRd/year > 90th 
percentile) and referral for aortic surgery.
Methods
Study Design
We performed a post hoc analysis of data from the PHN 
randomized clinical trial of atenolol versus losartan in chil-
dren and young adults with MFS. The trial design and main 
results have been previously reported [16, 17]. The main 
trial protocol was approved by the institutional review board 
or ethics committee at each participating study center, and 
informed consent and assent were obtained. The clinical data 
and the echocardiograms were collected from 21 participat-
ing centers. The echocardiograms were read in a core labora-
tory and the data used for this analysis were the measures at 
baseline, 12, 24, and 36 months after randomization.
Participants
The PHN MFS trial enrolled 608 subjects aged 6 months 
to 25 years who met the original Ghent diagnostic criteria 
for MFS [18], with an AoRz > 3 and AoRd < 5 cm. Patients 
who had previous aortic surgery, planned aortic surgery 
within 6 months of enrollment, or a history of aortic dissec-
tion were excluded from the trial. Data from all participants 
were analyzed except for 6 subjects with change in AoR 
z-score ≤ − 3 or ≥ 3 SD units/year, which were considered 
clinically implausible and attributed to measurement error.
Predictors
The baseline clinical characteristics, echocardiographic 
measures, and the maintenance doses of study drugs by 
treatment arm, which were considered as predictors, are 
included in Table 1. Seven outlier values among the pre-
dictors were identified and excluded from analysis to avoid 
undue influence on the results.
Outcomes
The outcomes for this analysis were (1) annual rate of 
change in AoR dilation (AoRz/year and AoRd/year); (2) 
rapid aortic dilation defined as change in AoRz/year and 
AoRd/year > 90th percentile; and (3) referral for aortic 
surgery.
Statistical Analysis
All analyses were conducted using SAS v9.3 (SAS Institute 
Inc., Cary, NC).
Rate of Aortic Dilation/Year and Rapid Aortic Root Dilation
Repeated measures multivariable linear and logistic regres-
sions with compound symmetric variance structure were 
used to assess variables associated with rate of AoR dilation 
and rapid AoR dilation, as defined above. A confirmatory 
analysis with multiple imputation showed similar results 
(data not shown).
Referral for Aortic Root Surgery
Multivariable logistic regression was used to assess vari-
ables associated with referral for aortic surgery. C-statistics 
were performed to generate receiver operator characteristic 
(ROC) curves to determine cut-points in AoR dilation pre-
dicting referral for aortic surgery. The cut-point was chosen 
as the point on the ROC curve that maximizes Youden’s 
Index.
Multivariable Modeling Procedures
Predictors significant at level 0.20 in binary analysis were 
entered into a multivariate model with backwards elimina-
tion. A P value < 0.05 was accepted for statistical signifi-
cance. The amount of variance explained by the models (R2) 
was examined. Since many of the predictors were derived 
from echocardiographic measurement of aortic dimensions, 
cluster analysis and correlations were examined to evalu-
ate the collinearity. For highly collinear variables (correla-
tions ≥ 0.8), only the predictor considered most clinically rel-
evant from each group was chosen to include in the models. 
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Table 1  Predictors Predictors N Mean ± SD or n (%)
Baseline clinical characteristics
 Age (years) 606 11.2 ± 6.3
 Male gender 608 366 (60%)
 Hispanic 607 82 (14%)
 Race 608
  White 526 (87%)
  Black or African American 46 (8%)
  Asian 16 (3%)
  Other 20 (3%)
 Family history (any relative with Marfan syndrome) 585 361 (62%)
 Prior cardiac surgery (non-aortic) 608 12 (2%)
 Prior medication use
  Beta blocker 608 344 (57%)
  Angiotensin converting enzyme inhibitors 608 34 (6%)
  Calcium channel blocker 608 8 (1%)
  Angiotensin receptor blocker 608 18 (3%)
  Other anti-hypertensive 608 2 (< 1%)
 Any endocrine history 608 7 (1%)
 Any neurodevelopmental history 608 117 (19%)
 Any psychiatric history 608 39 (6%)
 Height-for-age z-scorea 541 1.97 ± 1.14
 Weight-for-age z-scorea 548 0.31 ± 1.14
 BMI-for-age z-score 513 − 1.21 ± 1.66
 Systolic BP-for-age z-score 606 − 0.64 ± 0.98
 Diastolic BP-for-age z-score 606 0.32 ± 0.94
 Mean BP-for-age z-score 595 − 0.24 ± 0.96
 Pulse pressure (mmHg) 606 39 ± 9
 Resting heart rate-for-age z-score 604 − 0.01 ± 0.92
 Average 24-h heart rate-for-age z-score 608 0.63 ± 0.67
Baseline echocardiographic measures
 Aortic annulus z-score (SD units) 589 1.76 ± 1.30
 Aortic annulus diameter (cm) 589 2.01 ± 0.42
 Aortic root z-score (SD units) 607 4.32 ± 1.35
 Aortic root diameter (cm) 607 3.36 ± 0.61
 Sinotubular junction z-score (SD units) 552 2.12 ± 1.27
 Sinotubular junction diameter (cm) 552 2.41 ± 0.53
 Ascending aortic z-score (SD units) 543 1.00 ± 1.00
 Ascending aortic diameter (cm) 543 2.29 ± 0.49
 Aortic root diameter:aortic annulus diameter ratio 589 1.68 ± 0.17
 Sinotubular junction diameter:aortic annulus diameter ratio 543 1.22 ± 0.15
 Sinotubular junction diameter:aortic root diameter ratio 552 0.73 ± 0.06
 Sinotubular junction diameter:ascending aortic diameter ratio 506 1.06 ± 0.10
 Ascending aortic diameter:aortic annulus diameter ratio 531 1.16 ± 0.14
 Ascending aortic diameter:aortic root diameter ratio 543 0.69 ± 0.08
 Aortic root diameter:height ratio 540 0.023 ± 0.0025
 Ascending aortic diameter:height ratio 527 0.016 ± 0.0019
 Aortic root elastic modulus 598 101 ± 71
 Aortic root stiffness index 598 9.9 ± 6.5
 Ascending aortic elastic modulus 492 50 ± 28
 Ascending aortic stiffness index 492 5.0 ± 2.8
 Pediatric Cardiology
1 3
Consequently, only AoRd was included and aortic annulus, 
sinotubular junction, and ascending aortic dimensions were 
not, and only the stiffness index for AoR and ascending aorta 
were included, and the elastic modulus for both were not. A 
confirmatory analysis including or excluding these collinear 
predictors showed similar results (data not shown).
Since the effect of age on AoR dilation is not linear, age 
was plotted against outcomes, with a Loess (non-parametric) 
curve overlaid to assess the shape of the relationship between 
age and outcomes (Fig. 1a, b). The Loess (non-parametric) 
curves suggested a non-linear, but age group-dependent, 
effect of age on AoR dilation. On the basis of these curves, 
we used age cut-points for AoRz of 11 and 15 years for girls 
and 11 and 16 years for boys. For AoRd, we used cut-points 
of 8 and 14 for both genders. For referral for aortic surgery, 
a quadratic effect of age was chosen.
a Only available age ≤ 20 years
Table 1  (continued) Predictors N Mean ± SD or n (%)
Study drug by treatment arm
 Atenolol maintenance dose (mg/kg/day) 303 2.7 ± 1.1
 Losartan maintenance dose (mg/kg/day) 305 1.3 ± 0.2
Fig. 1  a, b The Loess (non-parametric) curves, that were used to 
assess the relationship of the annual changes in AoRz and AoRd with 
age, as solid red lines with the dotted red lines representing the 95% 
confidence intervals. c, d The ROC curves that were used to deter-
mine the AoR dilation cut-points in annual changes in AoRz and 





The mean age of the analytic cohort was 11.2 ± 6.3 years 
with the majority being male (60%) and white (87%) 
(Table 1). The mean baseline AoRz was 4.32 ± 1.35 SD units 
and AoRd was 3.36 ± 0.61 cm.
Independent of study arm, on medical treatment with 
atenolol or losartan, the mean annual change in AoRz was 
a decrease of − 0.13 ± 0.70 SD units/year, and the mean 
annual change in AoRd was an increase of 0.07 ± 0.18 cm/
year (Table 2). In this study cohort, the cut-off for rapid 
AoR root dilation > 90th percentile was > 0.64 SD units/
year for AoRz and > 0.26 cm/year for AoRd. During the 
study period, 28 subjects (5%) were referred for aortic root 
surgery including 2 (0.33%) subjects who underwent aortic 
root surgery for aortic dissection. There was one death due 
to congestive heart failure; this subject had neither aortic 
dissection nor aortic root surgery.
In the multivariable analysis (Table 3), an increased 
change in AoRz/year was associated with older age, a higher 
sinotubular junction diameter:AoR diameter ratio, and male 
gender (R2 = 0.02). An increased change in AoRd/year was 
associated with younger age, higher sinotubular junction 
z-score, male gender, and the absence of any psychiatric his-
tory (R2 = 0.07). Rapid AoR dilation, as defined by change in 
AoRz/year > 90th percentile, was associated with older age, 
higher sinotubular junction z-score, and atenolol as the study 
drug (R2 = 0.02). Rapid AoR dilation, as defined by change 
in AoRd/year > 90th percentile, was associated with higher 
sinotubular junction z-score and non-white race (R2 = 0.01). 
Table 2  Outcomes
AoR aortic root, AoRz AoR z-score, AoRd AoR diameter
a Of 1824 potential measures (3 annual changes per each of 608 sub-
jects)
Outcomes N Mean ± SD or n (%)
AoR dilation
 Annual change in AoRz/year (SD 
units/year)
1659a − 0.13 ± 0.70
 Annual change in AoRd/year (cm/
year)
1661a 0.07 ± 0.18
Referral for aortic surgery 608 28 (5%)
Table 3  Results of multivariable analysis
AAo ascending aorta, AoR aortic root, AoRz AoR z-score, AoRd AoR diameter, CL confidence limits, OR odds ratio, SE standard error, STJ sino-
tubular junction
Outcomes Predictors Slope SE P R2
AoR dilation
 Annual change in AoRz/year Created age variable: increase from child to young 
adult, with linear increase from age 11 to 15 for girls 
or 16 for boys
0.16 0.035 < 0.001 0.02
STJ diameter:AoR diameter ratio 0.62 0.26 0.02
Female gender − 0.076 0.032 0.02
 Annual change in AoRd/year Created age variable: number of years younger than 8 
(negative, or 0 if ≥ 8)
− 0.011 0.0030 < 0.001 0.07
Created age variable: number of years older than 14 (or 
0 if ≤ 14)
− 0.0077 0.0013 < 0.001
STJ z-score (SD) 0.012 0.0036 < 0.001
Female gender − 0.030 0.0084 < 0.001
Psychiatric history − 0.035 0.017 0.03
Outcomes Predictors OR CL P R2
Rapid AoR dilation
 Annual change in AoRz/year > 90th percentile Created age variable: increase from child to young 
adult, with linear increase from age 11 to 15 for girls 
or 16 for boys
1.71 1.17–2.49 0.005 0.02
STJ z-score (SD) 1.24 1.05–1.45 0.009
Study drug losartan vs. atenolol 0.72 0.52–1.00 0.05
 Annual change in AoRd/year > 90th percentile STJ z-score (SD) 1.31 1.12–1.52 < 0.001 0.01
Race other vs. white 5.48 1.15–26.18 0.03
Referral for aortic surgery AoR diameter (cm) 172 23 to > 999 < 0.001 0.17
AAo z-score (SD) 2.57 1.37–4.81 0.003
STJ diameter:AAo diameter ratio 811 4 to > 999 0.01
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Referral for aortic root surgery was associated with higher 
AoRd, higher ascending aorta z-score, and higher sino-
tubular junction diameter:ascending aorta diameter ratio 
(R2 = 0.17). Although statistically significant, the associa-
tions were weak, and none of the above-described clinical or 
echocardiographic factors were found to be robust predictors 
of AoR dilation or referral for aortic surgery.
ROC curves for change in AoRz and AoRd are shown 
(Fig. 1c, d). A change of AoRz of 0.72 SD units/year had 
42% sensitivity and 92% specificity for predicting referral for 
aortic surgery, and a change in AoRD of 0.34 cm/year had 
38% sensitivity and 95% specificity for predicting referral 
for aortic surgery.
Discussion
In this post hoc analysis of the data from the PHN Marfan 
trial, we did not find any robust clinical or echocardiographic 
predictors of rapid AoR dilation or referral for aortic sur-
gery in children and young adults with MFS monitored over 
3 years. Although some associations were statistically sig-
nificant, these associations were only weakly predictive and 
explained little of the variation in outcomes. In this study 
cohort, AoR dilation cut-points had high specificity, but low 
sensitivity for predicting referral for aortic surgery.
Previous studies have shown larger baseline AoR dimen-
sions to predict progressive AoR dilation in MFS. In 19 
children with MFS (aged 1–18 years) followed by echocar-
diography for up to 8 years, those with AoRz > 2 at baseline 
showed more rapid AoR dilation [9]. In 78 adults with MFS 
(aged 18–50 years) with a median echocardiography follow-
up of 71 months, baseline AoRd was the major predictor for 
progressive aortic root dilation (OR 1.37, 95% CI 1.16–1.62) 
[10].
We found progressive AoR dilation as measured by an 
increased change in AoRz/year was associated with older 
age, a higher sinotubular junction diameter:AoR diameter 
ratio, and male gender, whereas AoR dilation as measured 
by increased change in AoRd/year was associated with 
younger age, higher sinotubular junction z-score, male gen-
der, and absence of any psychiatric history. We postulate that 
the differential effect of age here is due to somatic growth in 
childhood. Younger individuals with MFS tend to maintain 
a similar AoRz throughout childhood, as their AoR grows 
in parallel to their more advanced somatic growth. Older 
individuals with MFS tend to have increasing AoRz, as 
their AoR continues to grow in adulthood, but their body 
surface area becomes fixed once somatic growth is com-
plete. In contrast, AoRd in all age groups with MFS tends 
to increase. We also found that more rapid AoR dilation as 
defined by change in AoRz/year > 90th percentile was asso-
ciated with older age, higher sinotubular junction z-score, 
and atenolol, whereas more rapid AoR dilation as defined by 
change in AoRd/year > 90th percentile was associated with 
higher sinotubular junction z-score, and non-white race. 
Although these associations were only weakly predictive, a 
common theme in these models was an increased sinotubular 
junction z-score and an increase in the sinotubular junction 
dimension relative to the AoR or ascending aortic dimen-
sion, or the so-called effacement of the sinotubular junction. 
This may suggest that monitoring the sinotubular junction 
dimensions by echocardiography could be an additional use-
ful marker of more rapid AoR dilation, both clinically and 
in future studies. However, data reported previously from 
this trial suggested that the maximum sinotubular junction 
diameter was one of the least consistently measured of the 
proximal aortic dimensions with the highest interobserver 
variability [19]. Therefore, simply recognizing effacement 
of the sinotubular junction by echocardiography might prove 
more useful than actually monitoring the sinotubular junc-
tion dimensions.
Similarly, aortic complications in MFS have previously 
been shown to be consistently associated with larger baseline 
AoR dimensions [4, 11–15]. In 113 patients with MFS (aged 
6 months to 66 years), with a mean follow-up of 49 ± 24 
months, aortic complications (dissection, marked dilation 
requiring surgery, or progressive moderate-to-severe aortic 
regurgitation) were associated with larger baseline AoRd, 
older age, increased height, higher systolic blood pressure, 
and AoR growth rate, but the only independent predictor 
was baseline AoRd [4]. Interestingly, when AoRd, one of 
the indications for surgical referral, was excluded from their 
analyses, the only independent predictor of aortic complica-
tions was generalized proximal aortic dilation involving the 
AoR, sinotubular junction, and ascending aorta, which was 
present in 51% of their study participants. AoR growth rate 
has also been shown previously to be associated with aortic 
complications in MFS in other studies. In 62 patients with 
MFS (aged 1 months to 54 years) with echocardiography 
follow-up for up to 16 years, aortic complications were again 
associated with larger baseline AoRd and older age, along 
with AoR growth rate > 5% per year [11]. In 57 children with 
MFS (aged 1–16 years) with echocardiography follow-up 
for up to 14 years, AoR growth rate was also shown to be of 
prognostic value for occurrence of aortic complications [12]. 
In 43 patients with MFS (aged 22 ± 14 years) with a mean 
echocardiography follow-up of 5 ± 3 years, aortic dissection 
both in the ascending and descending aorta only occurred in 
the group with more rapid AoR growth rate > 3% per year 
[13].
We found that referral for aortic root surgery was associ-
ated with higher AoRd, higher ascending aorta z-score, and 
higher sinotubular junction diameter:ascending aorta diame-
ter ratio. The higher sinotubular junction diameter:ascending 
aorta diameter ratio again suggests effacement of the 
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sinotubular junction. Along with the higher ascending aorta 
z-score, this suggests that generalized proximal aortic dila-
tion as has previously been shown [4] is associated with 
referral for aortic root surgery. As above, this may suggest 
that recognizing effacement of the sinotubular junction and 
generalized proximal aortic dilation could be useful clinical 
markers in determining the need for referral for aortic root 
surgery.
The main limitation of this study cohort is the short 
follow-up duration of only 3 years. The selection of only 
patients with moderate AoR disease, with AoRz > 3 and 
AoRd < 5 cm, and no potential for aortic surgery within 
6 months of enrollment, also limited the numbers of refer-
rals for aortic surgery during the study period. There was 
also likely variation in institutional criteria for referral for 
aortic surgery, as this was not prescribed within the main 
trial protocol. Including specific details about any family his-
tory of early dissection or need for aortic surgery may have 
added to our analysis. Genetic screening for the presence 
of an FBN1 mutation was only available in just over half of 
study participants, so was also not included in this analysis. 
Future planned genotype-specific and pharmacogenetics 
studies may provide additional information.
In conclusion, our analysis of data from a large rand-
omized study of children and young adults with MFS did not 
identify any new clinical or echocardiographic predictors of 
aortic root dilation or referral for aortic root surgery. Fur-
ther work may determine whether other risk factors, beyond 
baseline AoR dimensions (AoRz and AoRd) and AoR 
growth rate, such as generalized proximal aortic dilation 
and effacement of the sinotubular junction, may allow for 
better risk stratification. Rate of AoR dilation cut-points had 
high specificity, but low sensitivity for predicting referral for 
aortic surgery, limiting their clinical use. Establishment of 
registries monitoring patients with MFS longer term would 
allow us to determine whether such factors and family- and/
or genotype-specific predictors, may aid in identifying those 
patients who would most benefit from more frequent follow-
up and initiation of earlier medical therapy and/or surgical 
intervention.
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